Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063320 · ClinicalTrials.gov registry record · NA
The Effect of Spice Consumption on Postprandial Vascular Function
A NA study of Cardiovascular Risk Factor, sponsored by Penn State University.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03063320: Completed NA study of Cardiovascular Risk Factor, sponsored by Penn State University.
NCT03063320 is a NA study of Cardiovascular Risk Factor that has completed, run by Penn State University. The registered enrollment target is 43 participants, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03063320, a NA study of Cardiovascular Risk Factor, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
A 3-period randomized cross-over, controlled feeding study will be conducted to determine the effect of chronic spice consumption on postprandial vascular function. Participants will consume three test diets containing different amounts of spice. Each treatment period will last for 4 weeks. After each diet period a meal test will be conducted. Participants will consume a meal with a spice content corresponding to the diet period they have just completed. Endothelial function will be measured at 2 and 4 hours after meal consumption. Blood samples will also be taken during the 4 hours after meal consumption for measurement of lipids, immune and inflammatory markers.
Primary Outcome
Endothelial function measured by FMD
Conditions Studied
Interventions
- OTHER Spice blend
Study Locations (1)
Pennsylvania
- Penn State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-01-25 |
| Est. Completion | 2020-02-26 |
| Phase | NA |
What the finished NCT03063320 record still lists
NCT03063320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 1 intervention - of which Spice blend is the first listed.
NCT03063320 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03063320 about?
NCT03063320 is a clinical study titled "The Effect of Spice Consumption on Postprandial Vascular Function". A 3-period randomized cross-over, controlled feeding study will be conducted to determine the effect of chronic spice consumption on postprandial vascular function. Participants will consume three test diets containing different amounts of spice. Each treatment period will last for 4 weeks. After ea...
What is the current status of trial NCT03063320?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2017-01-25. Estimated completion is 2020-02-26.
What conditions does trial NCT03063320 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor.
What interventions are being tested in trial NCT03063320?
The interventions under investigation include: Spice blend (OTHER).
Who is sponsoring clinical trial NCT03063320?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03063320 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03063320's enrollment target sits among peer trials
43 22nd of 31 higher than 10 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
-
Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans
RECRUITING · NA
-
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI